CN113373214B - Use of CD30 in diagnosing brain nerve related diseases - Google Patents
Use of CD30 in diagnosing brain nerve related diseases Download PDFInfo
- Publication number
- CN113373214B CN113373214B CN202110680740.4A CN202110680740A CN113373214B CN 113373214 B CN113373214 B CN 113373214B CN 202110680740 A CN202110680740 A CN 202110680740A CN 113373214 B CN113373214 B CN 113373214B
- Authority
- CN
- China
- Prior art keywords
- serum
- fold
- dementia
- reagent
- assay
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 title claims abstract description 37
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 title claims abstract description 37
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract description 17
- 201000010099 disease Diseases 0.000 title abstract description 16
- 210000004556 brain Anatomy 0.000 title description 7
- 210000005036 nerve Anatomy 0.000 title description 4
- 210000002966 serum Anatomy 0.000 claims abstract description 20
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 17
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 15
- 230000002093 peripheral effect Effects 0.000 claims abstract description 5
- 238000000034 method Methods 0.000 claims description 26
- 239000003153 chemical reaction reagent Substances 0.000 claims description 25
- 208000024827 Alzheimer disease Diseases 0.000 claims description 13
- 238000003556 assay Methods 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 210000004369 blood Anatomy 0.000 claims description 5
- 239000008280 blood Substances 0.000 claims description 5
- 238000002965 ELISA Methods 0.000 claims description 3
- 238000003127 radioimmunoassay Methods 0.000 claims description 3
- 238000001262 western blot Methods 0.000 claims description 3
- 230000000295 complement effect Effects 0.000 claims description 2
- 238000003271 compound fluorescence assay Methods 0.000 claims description 2
- 238000000684 flow cytometry Methods 0.000 claims description 2
- 238000011532 immunohistochemical staining Methods 0.000 claims description 2
- 238000001114 immunoprecipitation Methods 0.000 claims description 2
- 238000004949 mass spectrometry Methods 0.000 claims description 2
- 238000012545 processing Methods 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims 1
- 230000003920 cognitive function Effects 0.000 abstract description 4
- 230000003340 mental effect Effects 0.000 abstract description 4
- 238000012216 screening Methods 0.000 abstract description 3
- 238000012795 verification Methods 0.000 abstract description 3
- 230000007423 decrease Effects 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 description 18
- 208000019901 Anxiety disease Diseases 0.000 description 11
- 238000001514 detection method Methods 0.000 description 10
- 230000036506 anxiety Effects 0.000 description 9
- 208000011580 syndromic disease Diseases 0.000 description 9
- 239000000203 mixture Substances 0.000 description 8
- 208000020016 psychiatric disease Diseases 0.000 description 8
- 210000003792 cranial nerve Anatomy 0.000 description 7
- 208000020401 Depressive disease Diseases 0.000 description 6
- 201000004810 Vascular dementia Diseases 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 5
- 239000012634 fragment Substances 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 201000000980 schizophrenia Diseases 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 108091093088 Amplicon Proteins 0.000 description 2
- 208000019022 Mood disease Diseases 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000000698 schizophrenic effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- HUDPLKWXRLNSPC-UHFFFAOYSA-N 4-aminophthalhydrazide Chemical compound O=C1NNC(=O)C=2C1=CC(N)=CC=2 HUDPLKWXRLNSPC-UHFFFAOYSA-N 0.000 description 1
- 108010000239 Aequorin Proteins 0.000 description 1
- 208000017194 Affective disease Diseases 0.000 description 1
- 239000012099 Alexa Fluor family Substances 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 108091033409 CRISPR Proteins 0.000 description 1
- 238000010354 CRISPR gene editing Methods 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- 206010067889 Dementia with Lewy bodies Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 201000011240 Frontotemporal dementia Diseases 0.000 description 1
- 206010021137 Hypovolaemia Diseases 0.000 description 1
- 206010065042 Immune reconstitution inflammatory syndrome Diseases 0.000 description 1
- 201000002832 Lewy body dementia Diseases 0.000 description 1
- 206010024419 Libido decreased Diseases 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 208000037490 Medically Unexplained Symptoms Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 208000002151 Pleural effusion Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- JQRLYSGCPHSLJI-UHFFFAOYSA-N [Fe].N1C(C=C2N=C(C=C3NC(=C4)C=C3)C=C2)=CC=C1C=C1C=CC4=N1 Chemical class [Fe].N1C(C=C2N=C(C=C3NC(=C4)C=C3)C=C2)=CC=C1C=C1C=CC4=N1 JQRLYSGCPHSLJI-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 101150038500 cas9 gene Proteins 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 238000002509 fluorescent in situ hybridization Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008717 functional decline Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000003209 gene knockout Methods 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 238000012226 gene silencing method Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000012165 high-throughput sequencing Methods 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000007658 neurological function Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- RXNXLAHQOVLMIE-UHFFFAOYSA-N phenyl 10-methylacridin-10-ium-9-carboxylate Chemical compound C12=CC=CC=C2[N+](C)=C2C=CC=CC2=C1C(=O)OC1=CC=CC=C1 RXNXLAHQOVLMIE-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/30—Psychoses; Psychiatry
- G01N2800/301—Anxiety or phobic disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/30—Psychoses; Psychiatry
- G01N2800/304—Mood disorders, e.g. bipolar, depression
Abstract
The inventor screens proteins which are possibly related to cognitive function decline by screening proteins which are differentially expressed in peripheral venous blood serum of young men facing larger mental stress before and after performing tasks for a long time, and collects patient cases for further verification, so that the concentration of CD30 in the serum of a subject can be proved to be used for diagnosing cognitive function related diseases.
Description
Technical Field
The invention relates to the field of biotechnology and biological medicine, in particular to application of CD30 in diagnosing brain nerve related diseases.
Background
Dementia is a brain disease, which is a disease caused by abnormal degeneration of the brain. Statistics show that patients are mostly old people, and clinical manifestations are: patients suffer from brain functional decline, whether in memory, operation, learning, understanding, even language, judgment, sense of direction, etc. The disease not only causes pain to the patient, but also causes a very negative effect to the family and the whole society. With the increase of the elderly, the number of patients suffering from senile dementia is increasing. Alzheimer's Disease (AD), a common form of degenerative dementia, is also known as Alzheimer's disease. Currently, more than 2500 ten thousand AD patients worldwide exist. Because of the characteristics of the disease age group, the Chinese medicinal composition is valued by the country in the aging stage, so the Chinese medicinal composition has great significance for the research of AD.
Depressive disorder is one of the most common mental disorders in the population, and the world health organization WHO survey results show that the incidence rate of depression is about 3.1% worldwide. Depression is a mood disorder or affective disorder caused by a variety of factors. Mainly manifested by low emotion, slow thinking, hypovolemia, cognitive impairment, loss of activity interest and ability, loss of self-esteem, improper feelings of guilt, death and suicidal thoughts, reduced concentration of attention, sleep disorders and appetite, hyposexuality, and various somatic symptoms. In developed western countries, the incidence of life-long depression is between 6% and 8%, and with progressive aging of the population, the incidence of depression in people over 60 years will be as high as 20% to 50%. The pathogenesis of depression is very complex, and the occurrence of depression may be associated with imbalance in neurological function of monoamine transmitters in the brain.
Disclosure of Invention
The inventor screens proteins which are possibly related to cognitive functions by screening proteins which are differentially expressed in peripheral venous blood serum before and after a young man who faces greater mental and mental pressures for a long time performs important tasks, and collects patient cases for further verification, so that the concentration of CD30 in the serum of a subject can be proved to be used for diagnosing brain nerve related diseases.
Use for diagnosing diseases
In one aspect, the invention provides the use of an agent for detecting the amount of CD30 expressed in the manufacture of a product for diagnosing whether a subject has a cranial nerve related disorder.
Preferably, the cranial nerve related disease includes mental disease and/or dementia.
Preferably, the mental disorder comprises anxiety and/or depression.
Preferably, the mental disorder is depression anxiety.
Preferably, the dementia includes Alzheimer's disease, vascular dementia, frontotemporal dementia, dementia with Lewy bodies, parkinson's disease.
Preferably, the dementia is Alzheimer's disease and/or vascular dementia.
Preferably, the CD30 is highly expressed in the patient.
Preferably, high expression means that the level of CD30 expression is at least 1.1 fold, e.g. at least 1.1 fold, 1.2 fold, 1.3 fold, 1.4 fold, 1.5 fold, 1.6 fold, 1.7 fold, 1.8 fold, 1.9 fold, 2.0 fold, 2.1 fold, 2.2 fold, 2.3 fold, 2.4 fold, 2.5 fold, 2.6 fold, 2.7 fold, 2.8 fold, 2.9 fold, 3.0 fold, 3.1 fold, 3.2 fold, 3.3 fold, 3.4 fold, 3.5 fold or more relative to the level of control expression in a healthy control population.
Preferably, the reagent for detecting CD30 expression level includes a reagent for detecting CD30 protein expression level and/or CD30mRNA expression level.
Preferably, the reagent for detecting the expression amount of CD30 protein includes a reagent used in the following method: western Blot (Western Blot), enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), sandwich assay, immunohistochemical staining, mass spectrometry, immunoprecipitation assay, complement fixation assay, flow cytometry fluorescence assay, and protein chip method.
Preferably, the reagent for detecting the expression level of CD30 protein includes a reagent used in a protein chip method.
Preferably, the chip used in the protein chip method is an AAH-BLG-1 chip of Raybiotech company.
Preferably, the reagent for detecting the expression level of the CD30 protein may further include an antibody or a fragment thereof of CD30, and the antibody or the fragment thereof of CD30 can specifically bind to the CD30 protein.
Preferably, the reagent for detecting the expression level of CD30 protein further comprises a secondary antibody which can bind to the antibody or a fragment thereof of CD30 and exhibit a detectable signal.
Preferably, the detectable signal may be emitted by a detectable label.
Preferably, the antibody or fragment thereof to CD30 may also be conjugated to a detectable label, the detection of which indicates the expression of both CD30 protein.
Preferably, the detectable label includes, but is not limited to, one or more of a fluorescent dye, a fluorescent molecule, a chemiluminescent label, biotin, a radioisotope.
Preferably, the fluorescent dye includes, but is not limited to, rhodamine, ROX, alexaFluor, ATTO, dylight, cyanine, fluoprobes, sulfoCy, seta, IRIS, seTau, SRfluor, square dyes.
Preferably, the fluorescent molecule comprises FAM, FITC, VIC, JOE, TET, CY, CY5, ROX, texas Red or LC Red460.
Preferably, the chemiluminescent label comprises a peroxidase, alkaline phosphatase, luciferase, aequorin, a functionalized iron-porphyrin derivative, luminol, isoluminol, acridinium ester, sulfonamide.
Preferably, the reagent for detecting the expression level of CD30mRNA includes reagents used in the following methods: PCR-based detection methods, southern hybridization methods, northern hybridization methods, dot hybridization methods, fluorescent in situ hybridization methods, DNA microarray methods, ASO methods, high throughput sequencing platform methods.
Preferably, reagents for collecting and/or processing samples are also included in the product.
Preferably, the sample comprises: serum, plasma, whole blood, urine, saliva, semen, milk, cerebral spinal fluid, tears, nasal epithelial cells, sputum, tissue, mucus, lymph, cytosol, ascites, pleural effusions, amniotic fluid, bladder irrigation fluid, and bronchoalveolar lavage fluid.
Preferably, the sample is serum.
Preferably, the serum is isolated from peripheral venous blood.
Product(s)
In another aspect, the invention provides a kit for diagnosing whether a subject has a cranial nerve related disease, the kit comprising reagents for detecting the expression level of CD30 in the subject.
Preferably, the kit may further comprise any one or more of the following: mRNA expression level auxiliary detection reagent, protein expression level auxiliary detection reagent, mRNA expression level auxiliary detection instrument, and protein expression level auxiliary detection instrument.
Preferably, the mRNA expression level-aiding detection reagent includes, but is not limited to: and (3) a reagent for visualizing the amplicon corresponding to the primer, such as a reagent for visualizing the amplicon by agarose gel electrophoresis, enzyme-linked gel method, chemiluminescence method, in situ hybridization method, fluorescence detection method and the like, an RNA extraction reagent, a reverse transcription reagent and a cDNA amplification reagent, and preparing a standard substance, a positive control substance and a negative control substance for a standard curve.
Preferably, the protein expression level-assisted detection reagent includes, but is not limited to: blocking solution, antibody diluent, washing buffer solution, chromogenic stop solution, and standard curve standard substance.
In another aspect, the invention provides a pharmaceutical composition for treating a cranial nerve related disease, the pharmaceutical composition comprising an inhibitor of CD30, the inhibitor being capable of knocking out the expressed gene of CD30 or reducing the content of CD 30.
Preferably, the inhibitor may be an antibody that specifically neutralizes CD 30.
Preferably, the inhibitor may also be an agent used by siRNA interference, CRISPR/cas9 methods, homologous recombination, gene knockout, gene replacement, gene silencing, site-directed mutagenesis, chemical pharmaceutical methods.
Preferably, the pharmaceutical composition may be in the form of tablets, pills, powders, granules, capsules, lozenges, syrups, liquids, emulsions, suspensions, controlled release formulations, aerosols, films, injections, intravenous drip agents, transdermal formulations, ointments, lotions, adhesive formulations, suppositories, pellets, nasal formulations, pulmonary formulations, eye drops and the like, oral or parenteral formulations.
Preferably, the cranial nerve related disease includes mental disease and/or dementia.
Preferably, the mental disorder is depression anxiety syndrome.
Preferably, the dementia is Alzheimer's disease and/or vascular dementia.
Method
In another aspect, the invention provides a method for diagnosing whether a subject has a cranial nerve related disease, the method comprising determining the disease status of the subject from the results of the detection of CD30 expression levels in the subject.
Preferably, the method further comprises the step of detecting the expression level of CD30 in the subject.
Preferably, the cranial nerve related disease includes mental disease and/or dementia.
Preferably, the mental disorder is depression anxiety syndrome.
Preferably, the dementia is Alzheimer's disease and/or vascular dementia.
Drawings
FIG. 1 is a graph showing the results of analysis of CD30 density differences in serum before and after the task of young men.
FIG. 2 is a graph showing the results of analysis of CD30 density differences in serum of control group and patient.
Fig. 3 is a ROC graph of anxiety-depressive syndrome diagnosis.
Fig. 4 is a ROC graph for dementia diagnosis.
Detailed Description
The present invention is further described in terms of the following examples, which are given by way of illustration only, and not by way of limitation, of the present invention, and any person skilled in the art may make any modifications to the equivalent examples using the teachings disclosed above. Any simple modification or equivalent variation of the following embodiments according to the technical substance of the present invention falls within the scope of the present invention.
Example 1 protein chip screening
For young men who are subjected to a large mental stress in performing a certain long-term task, peripheral venous blood is taken before and after the task is performed, wherein 8 samples before the task are performed and 12 samples after the task are performed. The target protein was selected from 507 factors using the AAH-BLG-1 chip from Raybiotech company. The read-out result is fluorescence intensity, and after normalization, the higher the value is, the higher the protein concentration is. As a result, the increase in CD30 in serum (p= 0.0331038) was found, and the specific results are shown in fig. 1.
Example 2 clinical verification and differential diagnosis of anxiety-depressive patients
Taking 5ml of elbow median venous blood of all the subjects, standing at room temperature for 30min, centrifuging at 1000 Xg for 15min, packaging and freezing in a-70 ℃ refrigerator. Serum was specifically analyzed for CD30 levels using a custom-made Raybiotech AAH-BLG-1 chip. Patient source and test data are shown in table 1 below.
Patients with depressive anxiety syndrome:
a total of 24 patients with depression anxiety syndrome who were treated in the first medical center of the general hospital for relief during the period from 6 months 2019 to 8 months 2019 (the first 24 test data in table 1, depression anxiety list). 19 patients with depression anxiety syndrome (25-43 test data in table 1) hospitalized in the fourth people hospital in city, sichuan province, 10 month 23 in 2020.
Patients with schizophrenia:
20 cases of schizophrenic patients (1-20 pieces of detection data in a column of schizophrenia in Table 1) are hospitalized in fourth-people hospitals in the city of Sichuan province, 10 months, 23 days 2020.
Dementia:
13 cases of Alzheimer's disease patients in the fourth people hospital in Du City, sichuan province, 10 months 2020, 6 cases of vascular dementia patients (Alzheimer's disease patients and vascular dementia patients data are combined into dementia, and the data are 19 data of one column of dementia in Table 1).
Control:
the control was derived from healthy volunteers who were examined by the first medical center of the general hospital of the same period of liberation army and all indexes were normal, and 20 cases were collected.
TABLE 1 CD30 levels in patient serum
Analysis of results:
anxiety depression syndrome: both patients with anxiety and depression syndrome in beijing and patients in Sichuan showed elevated serum CD30 levels, and the differences between beijing patients and healthy controls were significant (p= 0.003259), as well as those in Sichuan patients (p=0.00274). There was no statistical difference between Beijing patients and Sichuan patients. The results of the differential analysis of anxiety-depression syndrome are shown in the left panel of FIG. 2, and the diagnosed ROC curve is shown in FIG. 3.
Dementia: the difference between dementia patients and healthy controls was significant (p= 0.000529). The results of the differential analysis of anxiety-depression syndrome, schizophrenia and dementia are shown in the right graph of fig. 2. The ROC curve for dementia diagnosis is shown in fig. 4.
Patients with schizophrenia: there was no statistical difference between serum CD30 levels in schizophrenic patients and healthy controls.
The above data therefore show that CD30 has diagnostic significance and can be used in diagnosing anxiety depression and dementia, and that its elevated serum levels have a relationship with reduced cognitive function.
Claims (6)
1. Use of an agent for detecting the amount of soluble CD30 expressed in serum for the preparation of a product for diagnosing whether a subject has alzheimer's disease, said soluble CD30 being highly expressed in serum of a patient.
2. The use according to claim 1, wherein the agent for expressing the amount of soluble CD30 in serum comprises an agent used in the following method: western blot, enzyme-linked immunosorbent assay, radioimmunoassay, sandwich assay, immunohistochemical staining, mass spectrometry, immunoprecipitation assay, complement fixation assay, flow cytometry fluorescence assay techniques, and protein chip method.
3. The use according to claim 2, wherein the reagent for detecting the expression level of the soluble CD30 protein comprises a reagent used in a protein chip method.
4. The use of claim 1, wherein the reagents further comprise reagents for collecting and/or processing a sample.
5. The use of claim 4, wherein the sample is serum.
6. The use according to claim 5, wherein the serum is isolated from peripheral venous blood.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110680740.4A CN113373214B (en) | 2021-06-18 | 2021-06-18 | Use of CD30 in diagnosing brain nerve related diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110680740.4A CN113373214B (en) | 2021-06-18 | 2021-06-18 | Use of CD30 in diagnosing brain nerve related diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113373214A CN113373214A (en) | 2021-09-10 |
| CN113373214B true CN113373214B (en) | 2024-03-29 |
Family
ID=77577782
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110680740.4A Active CN113373214B (en) | 2021-06-18 | 2021-06-18 | Use of CD30 in diagnosing brain nerve related diseases |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113373214B (en) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103025890A (en) * | 2010-04-06 | 2013-04-03 | 卡里斯生命科学卢森堡控股 | Circulating biomarkers for disease |
| WO2017004243A1 (en) * | 2015-06-29 | 2017-01-05 | Caris Science, Inc. | Therapeutic oligonucleotides |
| CN106470681A (en) * | 2014-04-03 | 2017-03-01 | 茵维特丝肿瘤学私营有限责任公司 | Supramolecular assembly medicine |
| WO2017196432A1 (en) * | 2016-05-12 | 2017-11-16 | La Jolla Institute For Allergy And Immunology | Compositions and methods for diagnosing and treating neurodegenerative disease |
| CN108780084A (en) * | 2015-09-03 | 2018-11-09 | 诺华股份有限公司 | Predict the biomarker of cytokines release syndrome |
| EP3786298A1 (en) * | 2012-11-01 | 2021-03-03 | Factor Bioscience Inc. | Methods and products for expressing proteins in cells |
| CN112649608A (en) * | 2020-12-01 | 2021-04-13 | 中国人民解放军军事科学院军事医学研究院 | Application of MMP19 in serum in anxiety and depression |
-
2021
- 2021-06-18 CN CN202110680740.4A patent/CN113373214B/en active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103025890A (en) * | 2010-04-06 | 2013-04-03 | 卡里斯生命科学卢森堡控股 | Circulating biomarkers for disease |
| EP3786298A1 (en) * | 2012-11-01 | 2021-03-03 | Factor Bioscience Inc. | Methods and products for expressing proteins in cells |
| CN106470681A (en) * | 2014-04-03 | 2017-03-01 | 茵维特丝肿瘤学私营有限责任公司 | Supramolecular assembly medicine |
| WO2017004243A1 (en) * | 2015-06-29 | 2017-01-05 | Caris Science, Inc. | Therapeutic oligonucleotides |
| CN108780084A (en) * | 2015-09-03 | 2018-11-09 | 诺华股份有限公司 | Predict the biomarker of cytokines release syndrome |
| WO2017196432A1 (en) * | 2016-05-12 | 2017-11-16 | La Jolla Institute For Allergy And Immunology | Compositions and methods for diagnosing and treating neurodegenerative disease |
| CN112649608A (en) * | 2020-12-01 | 2021-04-13 | 中国人民解放军军事科学院军事医学研究院 | Application of MMP19 in serum in anxiety and depression |
Non-Patent Citations (6)
| Title |
|---|
| Chemokines, sTNF-Rs and sCD30 serum levels in healthy aged people and centenarians;R Gerli等;《Mech Ageing Dev》;20001220;第121卷(第1-3期);第37-46页 * |
| Gabriele Di Lorenzo等.Serum levels of soluble CD30 in adult patients affected by atopic dermatitis and its relation to age, duration of disease and Scoring Atopic Dermatitis index.Mediators Inflamm.2003,第12卷(第12期),123-125. * |
| Identification of Hippocampus-Related Candidate Genes for Alzheimer’s Disease;Keiko Taguchi等;《Ann Neurol》;20050430;第57卷(第4期);摘要，表1 * |
| Interleukin-18 and CD30 serum levels in patients with moderate-severe depression;Rosaria Alba Merendino等;《Mediators Inflamm》;20020831;第11卷(第4期);第265-267页 * |
| Ligands and receptors of the TNF superfamily are decreased in major depression and during early antidepressant therapy;Frank M Schmidt等;《J Psychiatr Res》;20191231;第119卷;摘要，第117页左栏第1段，第118页左栏倒数第2段，第118页右栏第4段，表2，图1 * |
| 抑郁症与心血管疾病关系的研究进展;李晔;《哈尔滨医科大学学报》;20130425;第47卷(第2期);第194-196页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113373214A (en) | 2021-09-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Guasp et al. | CSF biomarkers in COVID-19 associated encephalopathy and encephalitis predict long-term outcome | |
| Ottervald et al. | Multiple sclerosis: Identification and clinical evaluation of novel CSF biomarkers | |
| Lanni et al. | Conformationally altered p53: a novel Alzheimer's disease marker? | |
| JP2008544225A (en) | Methods and compositions for diagnosis of neurological disorders in body fluids | |
| US20190339291A1 (en) | Circulating biomarker levels for diagnosis and risk-stratification of traumatic brain injury | |
| JP2007513337A (en) | Diagnostic, stratified and monitoring methods for Alzheimer's disease | |
| CN102150043A (en) | Blood transcriptional signature of mycobacterium tuberculosis infection | |
| JP2018132526A (en) | Markers, method for inspection, and inspection kit for major depressive disorder and bipolar disorder, and method for screening therapeutic medicines for major depressive disorder and bipolar disorder | |
| Ya et al. | Differences in ABCA1 R219K polymorphisms and serum indexes in Alzheimer and Parkinson Diseases in Northern China | |
| Chen et al. | Changes in serum cystatin C levels and the associations with cognitive function in Alzheimer's disease patients | |
| Huang et al. | Predictive effect of Bayes discrimination in the level of serum protein factors and cognitive dysfunction in schizophrenia | |
| US20220098669A1 (en) | Gene signature for the prognosis of dry eye disease | |
| EP1876449A1 (en) | Cell cycle-based blood test to diagnose Alzheimer's disease | |
| CN113373214B (en) | Use of CD30 in diagnosing brain nerve related diseases | |
| CN110988351B (en) | Application of vascular cell adhesion molecule in preparing related products for diagnosis and treatment of depression | |
| Karim et al. | Serum levels of cadmium, calcium, lead and iron in schizophrenic patients | |
| US10900977B2 (en) | Protein biomarkers for memory loss | |
| CN108342468A (en) | CircRNA markers, kit and genetic chip for AD screenings | |
| CN113252910B (en) | Application of TIMP3 in anxiety and depression diagnosis | |
| Ren et al. | Effects of white matter lesion grading on the cognitive function of patients with chronic alcohol dependence | |
| CN113215249B (en) | IL-26 for the identification and diagnosis of anxious depression | |
| US20230273220A1 (en) | Methods for prediction, detection and monitoring of substanceuse disorders and/or an infection | |
| RU2788149C1 (en) | Proteins dclk1 and ripk1 biomarkers of simple schizophrenia | |
| CN109884297B (en) | Clinical markers for assessing susceptibility to ARTI in children | |
| Dharmawan et al. | The differences of blood type in relation to psoriasis and its onset: Cross sectional study |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |